GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XTL Biopharmaceuticals Ltd (FRA:H2K2) » Definitions » Net Margin %

XTL Biopharmaceuticals (FRA:H2K2) Net Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is XTL Biopharmaceuticals Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. XTL Biopharmaceuticals's Net Income for the three months ended in Mar. 2024 was €0.45 Mil. XTL Biopharmaceuticals's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, XTL Biopharmaceuticals's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for XTL Biopharmaceuticals's Net Margin % or its related term are showing as below:


FRA:H2K2's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

XTL Biopharmaceuticals Net Margin % Historical Data

The historical data trend for XTL Biopharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XTL Biopharmaceuticals Net Margin % Chart

XTL Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

XTL Biopharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of XTL Biopharmaceuticals's Net Margin %

For the Biotechnology subindustry, XTL Biopharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XTL Biopharmaceuticals's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where XTL Biopharmaceuticals's Net Margin % falls into.



XTL Biopharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

XTL Biopharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1.634/0
= %

XTL Biopharmaceuticals's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin=Net Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=0.446/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XTL Biopharmaceuticals  (FRA:H2K2) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


XTL Biopharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of XTL Biopharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


XTL Biopharmaceuticals Business Description

Traded in Other Exchanges
Address
26 Ben-Gurion Street, Ramat Gan, ISR, 5112001
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

XTL Biopharmaceuticals Headlines

No Headlines